This study will assess a device that combines CCM® Therapy and a single-chamber defibrillator for patients with heart failure and reduced ejection fraction.
You may be eligible for the study if you have been diagnosed with all of the following:
- Symptomatic NYHA Class III heart failure
- A left ventricular ejection fraction (LVEF or EF) that is 25 – 35%
- An NYHA Class I indication for an ICD
Full details and contact information on the study and participating hospitals will be updated regularly.
Research Institutions and Investigators
If you are interested in participating in the INTEGRA-D study, contact the Impulse Dynamics clinical team by clicking on the link below.